MindImmune Appoints Thomas Prod’homme, Ph.D., as Vice President, Preclinical Development
South Kingston, RI – April XX, 2025 – MindImmune Therapeutics, a biopharmaceuticalcompany focused on neuroinflammation and Alzheimer’s disease, has appointedThomas Prod’homme, Ph.D., as Vice President, Preclinical Development. Dr.Prod’homme will lead cross-disciplinary preclinical strategy for MindImmune’s pipeline,including its monoclonal antibody candidate MITI-101, designed to prevent therecruitment of neuroinflammatory innate immune cells from the periphery into the brainwhere they cause damage to brain cells underlying disease. His responsibilities includeguiding candidate selection and advancing preclinical studies including CMC, drugsafety evaluation and translational biomarkers to support clinical development.
“We couldn’t be more pleased that Thomas has joined the MindImmune team at thiscritical point in our growth,” said Stevin Zorn, PhD, co-founder, President and CEO ofMindImmune. “Thomas’s deep experience in translational medicine and immunology,and success in spearheading the filing of multiple IND applications and implementingclinical biomarker strategies will certainly add great value to the advancement of ourlead program, MITI-101.”
Dr. Prod’homme is a scientific leader with a 15-year history in drug discovery in both thebiotech and pharmaceutical industries. He has demonstrated success in building andleading preclinical and translational research infrastructures and regulatorysubmissions. Importantly, Dr. Prod’homme has spearheaded the successful filing ofmultiple IND applications and has authored over 20 scientific publications. Prior toMindImmune, Dr. Prod’homme held various positions of growing responsibilities inpharmaceutical and biotechnology companies, including, most recently, Head ofTranslational Research at Mirai Bio and Myeloid Therapeutics. Dr. Prod’hommereceived his Doctor of Philosophy (PhD) in Immunology, from the Université RenéDescartes in Paris and conducted postdoctoral fellowship studies in the Department ofNeurology at University of California San Francisco.
Dr. Prod’homme commented, “Joining the MindImmune team is a great opportunity forme to contribute to the company’s growth and to work alongside its founders who sharea collective vision to treat Alzheimer’s disease and other disorders related toneuroinflammation. I look forward to bringing my expertise to advancing MITI-101 andstarting IND-enabling work this year.”
About MindImmune Therapeutics
MindImmune Therapeutics is a venture-backed biopharmaceutical company pioneeringnovel treatments for neurodegenerative diseases by targeting neuroinflammation.Founded in collaboration with the University of Rhode Island’s Ryan Institute forNeuroscience, Mindimmune is advancing a bold scientific approach to halt the harmfulrecruitment of immune cells from the bloodstream into the brain. Its lead program, MITI-101, aims to intercept the immune response in Alzheimer’s and otherneurodegenerative disorders- offering the potential for a transformative breakthrough inthe treatment of these devastating conditions.
Since June 2022, MindImmune has raised financing of $19.4 million. Investorsparticipating include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s DrugDiscovery Foundation (ADDF), Gates Frontier Holdings, Foundation for a Better World, Trend Venture, RightHill Ventures, Slater Technology Fund and several privateinvestors.
Currently, MindImmune is planning a new financing round seeking investors to advanceMITI-101 into clinical development including an early read on efficacy in Alzheimer'sdisease.
For more information, please visit: www.mindimmune.com
Media Contact
Danielle DucheneInizio Evoke Comms
Danielle.duchene@inizioevoke.com